ACW confirms eligibility for further $1.9m RDTI
Filed with ASX · · 3 pages · English
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- ACW achieves early screening closure for XanaMIA trial
- ACW receives initial $5.5m R&D tax incentive rebate
- Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
- ACW successful FDA meeting on Alzheimers program
- Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states
Later from Actinogen Medical
- ACW September 2025 quarterly activity report & Appendix 4C
- ACW positive XanaMIA Data Monitoring Committee meeting
- ACW XanaMIA trial fully enrolled with 246th participant
- Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
- Actinogen secures $4.3m of non-dilutive R&D tax funding
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical